Grafa News and Videos — Page 83

First Citizens BancShares (NASDAQ:FCNCA) declared a quarterly common stock dividend of $2.25 per share, covering both Class A and Class B common shares.

Zymeworks (NASDAQ:ZYME) entered an exclusive global license and collaboration agreement with Roche for its experimental cancer treatment ZW209, with a $55 million upfront payment.

IDEAYA Biosciences (NASDAQ:IDYA) reported updated Phase 1 results for IDE849, showing a 60.8% confirmed objective response rate in second-line small cell lung cancer patients.

Flagstar Bank (NYSE:FLG) reported third-quarter 2026 net income attributable to common stockholders of $3 million, or $0.01 per diluted share, down from $26 million in the previous quarter.

Eni (NYSE:E) reported third-quarter 2026 adjusted net profit of €2.8 billion, more than doubling from a year earlier as higher production and a favorable commodity market supported earnings.

Phathom Pharmaceuticals (NASDAQ:PHAT) announced that BDR Pharmaceuticals International has filed a lawsuit against the U.S. Food and Drug Administration challenging regulatory exclusivity protections for VOQUEZNA tablets.

Singapore’s Monetary Authority has expanded its BLOOM initiative to include Malaysia and Thailand as policymaker members, strengthening regional cooperation on digital money settlement.

Veracyte (NASDAQ:VCYT) reported an analysis of Phase III STAMPEDE trial data suggesting its Decipher Prostate test may help identify patients who benefit from adding abiraterone to treatment.

Oil prices rose more than 1% on Friday as Houthi attacks in Saudi Arabia heightened concerns about further disruptions to energy supplies from the Middle East.

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported initial Phase 1b results showing that brezosiran reduced cerebrospinal fluid mutant huntingtin protein by an average of 60%–64% after three months in the highest dose group evaluated.